Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Aug 12, 2025
Episode
306
Soundcloud
Share
In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses HER2 non-small cell lung cancer and the recently approved zongertinib. Dr. Ibiayi Dagogo-Jack and Dr. Gerrina Ruiter join the conversation to help review the data and discuss its place in the management of patients with HER2-positive NSCLC.
Guest
Ibiayi Dagogo-Jack
MD
Thoracic Medical Oncologist
Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
Gerrina Ruiter
M.D., Ph.D.
Pulmonologist, Department of Thoracic Oncology, Department of Phase 1 Studies
Antoni van Leeuwenhoek – Netherlands Cancer Institute
